USA flag logo/image

An Official Website of the United States Government

Pre-Clinical Evaluation of Novel Peptidoglycan for Prevention of Hypertrophic…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
96206 		Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM093414 		Solicitation Year:
N/A 		Solicitation Topic Code:
NIGMS 		Solicitation Number:
N/A
Small Business Information
GLYTRIX, INC.
206 S MARTIN JISCHKE DRIVE WEST LAFAYETTE, IN 47907
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Pre-Clinical Evaluation of Novel Peptidoglycan for Prevention of Hypertrophic Sca
Agency: HHS
Contract: 1R43GM093414-01A1
Award Amount: $195,046.00
 

Abstract:

DESCRIPTION (provided by applicant): This proposal addresses PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]). Hypertrophic scars commonly form during healing of deep dermal wounds and are characterized as bulky, inelastic scars, which can restrict mobility, constrict orifices, and severely compromise physical appearance. According to Aetna, 10-15% of dermal wounds result in hypertrophic or keloid scars. The abnor mal healing mechanism giving rise to hypertrophic scars is not fully understood, however advances in the understanding of biochemical differences between healthy and hypertrophic tissue, such as extracellular matrix components and how they affect fibroblas t behavior, provide insights for development of therapeutic approaches for improving healing and reducing or eliminating scarring. Glytrix has designed a novel collagen-binding peptidoglycan, inspired by decorin, which regulates collagen fibril formation a nd increases collagen gel stiffness as decorin does. Using adult primary smooth muscle cells, higher elastin production was found in type I collagen gels in the presence of the peptidoglycan relative to collagen gels alone, thus demonstrating a positive im pact of peptidoglycans on adult cell healing. Recently, Glytrix has shown that one time introduction of the peptidoglycan into a full thickness dermal wound in a rat results in improved healing as determined by reduction in visible scar and improved wound tensile strength. Glytrix hypothesizes that introduction of collagen binding peptidoglycan into deep dermal wounds in a Red Duroc pig model will inhibit hypertrophic scar formation, reduce overall scarring and improve healing of the wounds. In addition, a functional assay for determining synthesis criteria of the peptidoglycan will be developed. At the completion of the 6 month project, Glytrix will be poised to scale up production with a contract manufacturing organization, and perform GMP/GLP preclinical and toxicity studies, which will be the focus of the Phase II proposal. PUBLIC HEALTH RELEVANCE: Hypertrophic scars commonly form during healing of deep dermal wounds including second and third degree burns, and are characterized as bulky, inelastic scars, which can restrict mobility, constrict orifices, and severely compromise physical appearance. Internal scarring can detrimentally affect healing following surgical procedures. The proposed work aims to evaluate a new potential therapeutic to inhibi t scar formation and restore normal healing.

Principal Investigator:

John Paderi

Business Contact:

Kate Stuart
kstuart@gytrix.com
Small Business Information at Submission:

GLYTRIX, INC.
206 S MARTIN JISCHKE DRIVE WEST LAFAYETTE, IN 47907

EIN/Tax ID: 127050457
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No